HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Change At Bayer Consumer Helm As Drive To Top Stalls

This article was originally published in The Pink Sheet

Executive Summary

Bayer hires Heiko Schipper away from Nestle's nutritional products business to succeed Erica Mann as its consumer division chief. Mann intended to resign at the end of 2018 but will step down early because Schipper will take the division top spot in March.

You may also be interested in...



Potential Buyers Assess Available OTC Assets From Disparate Views

As Merck KGAA and Pfizer shop their consumer health businesses, large pharmas J&J, Bayer AG and Sanofi, health and household care marketer Reckitt Benckiser and a smaller firm expanding its OTC focus, Prestige Brands, are among the firms with reasons to consider changing their own consumer health lineups.

Bayer ‘All Hands On Deck’ For US Consumer Business Turnaround

“There is a ton of work still for us to do,” Erica Mann, Bayer’s global consumer head, said after the firm reported disappointing second-quarter results. The root of the problem is over-estimating the revenue boost from former Merck & Co. brands, the firm says.

Bayer Lands Merck Consumer As Springboard to Lead Global OTC Industry

The $14.2 billion deal is “a major milestone on our path toward global leadership” in OTC sales, says Bayer Chairman Marijn Dekkers. The acquisition focuses on expanding international sales of Merck products including the Claritin allergy, Coppertone sunscreen and MiraLax constipation lines.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS122926

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel